Skip to content

Application of Platelet-Rich Plasma in Laryngopharyngeal Voice Disorders

Application of Platelet-Rich Plasma in Laryngopharyngeal Voice Disorders

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600116520
Enrollment
Unknown
Registered
2026-01-12
Start date
2026-01-19
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dysphonia

Interventions

Control group:Voice training
Intervention group:Autologous platelet-rich plasma (PRP) injection

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Age requirement: >=18 years; with full civil capacity and able to comply with follow-up and assessments. 2.Confirmed diagnosis: Diagnosed by videolaryngostroboscopy (dynamic laryngoscopy) as having at least one of the following benign conditions: vocal fold scar, sulcus vocalis, vocal fold atrophy, presbylaryngis, or other benign vocal fold disorders causing impaired vocal fold vibration (e.g., mild inflammatory lesions). 3.Clinical symptoms: Presence of functional voice impairment such as hoarseness, vocal fatigue, reduced vocal loudness, or abnormal voice quality; VHI-10 indicates moderate to severe voice handicap. 4.Previous treatment history: Prior treatments such as vocal fold surgery and/or vocal fold injection are allowed if symptoms have not significantly improved; no laryngeal surgery, injection, or other invasive laryngeal procedures within the past 3 months. 5.General condition: Generally healthy without severe systemic disease, and able to tolerate local injection procedures.

Exclusion criteria

Exclusion criteria: Exclusion criteria: Any laryngeal surgery or vocal fold augmentation injection within the past 3 months; active laryngeal infection/inflammation; coagulopathy, thrombocytopenia, or platelet function disorders; autoimmune disease, malignancy, severe liver disease, or significant respiratory functional limitation; allergy to lidocaine, amide-type local anesthetics, or bovine-derived products; coexisting laryngeal conditions that may confound efficacy assessment (e.g., marked vocal tremor or laryngeal dystonia/muscle tension dysphonia); pregnancy—pregnant individuals are not eligible to participate in this study.

Design outcomes

Primary

MeasureTime frame
Voice Handicap Index-10;Videolaryngostroboscopy parameters (glottal closure, mucosal wave amplitude/symmetry, vibratory amplitude);

Secondary

MeasureTime frame
Voice Fatigue Index;GRBAS perceptual rating scale ;Cepstral Spectral Index of Dysphonia(CSID);Jitter (%);Shimmer (%);Maximum phonation time (MPT);

Countries

China

Contacts

Public ContactYang Hui

West China Hospital, Sichuan University

yh8806@163.com+86 189 8060 1418

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026